The Era of Immunotherapy in Earlier Stages of Non-Small Cell Lung Cancer
(NSCLC): What Managed Care Needs to Know for
Improved Clinical and Economic Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of NSCLC, including
how to translate the most recent data into clinical and administrative practice.

These are archives of live webinars held between February 18 to February 27, 2020.
If you participated in any of the live webinars, you are not eligible
to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

Each session has its own specific valid dates

This series is supported by educational grants from
AstraZeneca and Merck & Co.
 

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Lung cancer is the worldwide leading cause of cancer-related mortality. The vast majority of these cases (about 85%) are characterized as non-small cell lung cancer (NSCLC). In recent years, NSCLC has been found to have a multidimensional typology and etiology driven by molecular changes in lung tissue. The knowledge that the molecular structure of tumor cells has been altered has led to the development of novel checkpoint inhibitors (ICI). It was only recently that ICIs have approved for treating patients with stage III disease following concurrent chemoradiation therapy, the aim of which is to prevent disease progression.

This live webinar series on stage three and earlier NSCLC will provide attendees with critical updates on the advances in ICIs, including how to translate the most recent data into clinical and administrative practice.

A Deeper Look into Immunotherapies in Stage III and Earlier Non-Small Cell Lung Cancer (NSCLC): Improving Clinical and Economic Outcomes

1. Identify current unmet clinical needs in the management of early stage NSCLC, including stage III disease, and evidence-based recommendations for the care of patients with these tumors
2. Explore how to harness the immune system in the treatment of cancer, mechanisms of action of the immune checkpoint inhibitors, and rationale for use of immunotherapy in stage III NSCLC as well as other earlier disease stage settings of lung cancer
3. Analyze key clinical data on the efficacy and safety of checkpoint inhibitor-based treatment of patients with stage III, locally advanced, unresectable NSCLC whose cancer has not progressed following chemoradiation therapy
4. Recognize the need for interventions that can delay NSCLC progression, and the rationale for using immune-checkpoint inhibitors for this purpose
5. Discuss the key clinical trials assessing immunotherapies and immune-based combinations in earlier stages of lung cancer, and the available data from such trials

Comparative Effectiveness and Coordinated Care in Stage III and Earlier Non-Small Cell Lung Cancer (NSCLC): What Does Managed Care Need to Know about Immunotherapies?

1. Identify key economic challenges surrounding management of patients with early stage NSCLC, including stage III disease
2. Discuss the managed care considerations of current and emerging immunotherapies by exploring where these agents fit into the current stage III and earlier NSCLC management paradigm
3. Analyze strategies used by managed care organizations to facilitate high quality care for members with stage III and earlier NSCLC, and how recent immunotherapy approvals will affect those strategies
4. Apply methods to enable optimal cost management of immunotherapies to be realized by multiple stage III and earlier NSCLC stakeholders including managed care organizations
5. Explain the role of the managed care professional in optimizing the use of checkpoint inhibitor therapy for unresectable stage III NSCLC and opportunities to advance managed care services

Improving Patient Adherence and Quality of Life in Stage III and Earlier Non-Small Cell Lung Cancer (NSCLC): Anticipating and Managing Immune-Related Adverse Events

1. Discuss challenges to patient adherence and quality of life when utilizing immunotherapy in stage III and earlier NSCLC
2. Explore strategies to monitor and manage adverse events associated with immunotherapies and immunotherapy combination options in stage III and earlier NSCLC in order to improve patient adherence and quality of life
3. Review recent clinical trial data around the safety of immunotherapies in stage III and earlier NSCLC, both alone and in combination, and their effect on patient quality of life
4. Address challenging questions regarding the management of stage III and earlier NSCLC and discuss ways the managed care physician, nurse, and pharmacist can aid in the implementation of clinical pathways to deliver quality care